CN1785230B - Delayed-release compounding Radix astragali gel skeleton tablets and its preparation method - Google Patents
Delayed-release compounding Radix astragali gel skeleton tablets and its preparation method Download PDFInfo
- Publication number
- CN1785230B CN1785230B CN 200410093886 CN200410093886A CN1785230B CN 1785230 B CN1785230 B CN 1785230B CN 200410093886 CN200410093886 CN 200410093886 CN 200410093886 A CN200410093886 A CN 200410093886A CN 1785230 B CN1785230 B CN 1785230B
- Authority
- CN
- China
- Prior art keywords
- radix
- extract
- radix astragali
- salviae miltiorrhizae
- lignum dalbergiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000009636 Huang Qi Substances 0.000 title claims description 78
- 238000002360 preparation method Methods 0.000 title claims description 15
- 238000013329 compounding Methods 0.000 title 1
- 230000003111 delayed effect Effects 0.000 title 1
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 45
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 227
- 239000000284 extract Substances 0.000 claims description 65
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 28
- 239000013563 matrix tablet Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 238000010992 reflux Methods 0.000 claims description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- -1 hydroxypropyl Chemical group 0.000 claims description 19
- 239000008101 lactose Substances 0.000 claims description 19
- 235000006533 astragalus Nutrition 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- 241000045403 Astragalus propinquus Species 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241001061264 Astragalus Species 0.000 claims description 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 2
- 239000009724 Salvia extract Substances 0.000 claims description 2
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 abstract description 5
- 235000005412 red sage Nutrition 0.000 abstract description 2
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 244000138993 panchioli Species 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 239000000706 filtrate Substances 0.000 description 42
- 239000000341 volatile oil Substances 0.000 description 24
- 238000010298 pulverizing process Methods 0.000 description 21
- 238000004064 recycling Methods 0.000 description 20
- 239000009277 Panax notoginseng extract Substances 0.000 description 19
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 19
- 244000132619 red sage Species 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 4
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000017276 Salvia Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229930189533 tanshinol Natural products 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410093886 CN1785230B (en) | 2004-12-10 | 2004-12-10 | Delayed-release compounding Radix astragali gel skeleton tablets and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410093886 CN1785230B (en) | 2004-12-10 | 2004-12-10 | Delayed-release compounding Radix astragali gel skeleton tablets and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1785230A CN1785230A (en) | 2006-06-14 |
CN1785230B true CN1785230B (en) | 2010-12-01 |
Family
ID=36782898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410093886 Expired - Fee Related CN1785230B (en) | 2004-12-10 | 2004-12-10 | Delayed-release compounding Radix astragali gel skeleton tablets and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1785230B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1349818A (en) * | 2001-10-24 | 2002-05-22 | 沈阳药科大学 | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process |
-
2004
- 2004-12-10 CN CN 200410093886 patent/CN1785230B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1349818A (en) * | 2001-10-24 | 2002-05-22 | 沈阳药科大学 | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process |
Also Published As
Publication number | Publication date |
---|---|
CN1785230A (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100450501C (en) | Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
CN103349671A (en) | Resveratrol and spirulina composition and preparations and preparation method thereof | |
CN1985891B (en) | Compound Chinese medicine preparation with liver protecting function and its preparing process | |
CN1887324B (en) | Chinese medicine composition for treating liver and kidney defect, and its preparation process and analysis method | |
CN103316074B (en) | Medicine composite of halenia corni extract, astragalus extract and liquorice extract as well as preparation and application of medicine composite | |
CN1785230B (en) | Delayed-release compounding Radix astragali gel skeleton tablets and its preparation method | |
CN100522210C (en) | Medicinal composition for treating aphronesia and preparing process thereof | |
CN102309543A (en) | Compound salvia miltiorrhiza concentrated preparation and preparation and detection method thereof | |
CN102048966A (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
CN102018740B (en) | Medicinal composition containing extracts of leaves of helianthus and application of the same | |
CN100411653C (en) | Chinese medicine composition for treating diabetes mellitus | |
CN101313989B (en) | Chinese medicinal composition for treating coronary disease, stenocardia | |
CN103961582A (en) | Traditional Chinese medicine composition for treating nephritis, and preparation and preparation method thereof | |
CN1785272B (en) | Medicinal composition and its preparation method | |
CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
CN109394968B (en) | Composition with auxiliary blood sugar reducing function and application thereof | |
CN109045240B (en) | Traditional Chinese medicine composition of Gaocheng preparation, preparation method, detection method and application thereof | |
CN103961428B (en) | A kind of detection method of the Chinese medicinal composition preparation with promoting flow of QI and blood effect | |
CN100444860C (en) | Compound Chinese medicinal extract mixture and its prepration method | |
CN101966219A (en) | Pseudoginseng root trialcohol group saponin extract and preparation process thereof | |
CN101966217A (en) | Pnaxtriol saponin extract and preparation process thereof | |
CN100579558C (en) | Quality control method of particles for treating cardio-cerebral vascular diseases | |
CN102302707B (en) | Philippine flemingia kidney meprobamate pharmaceutical composition, production method thereof, and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101201 Termination date: 20191210 |
|
CF01 | Termination of patent right due to non-payment of annual fee |